• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.托瑞帕利单抗联合化疗治疗转移性或复发性三阴性乳腺癌的TORCHLIGHT试验结果的通俗语言总结。
Future Oncol. 2025 Feb;21(4):421-429. doi: 10.1080/14796694.2024.2430106. Epub 2024 Dec 4.
2
A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).托瑞帕利单抗联合化疗治疗晚期非小细胞肺癌（NSCLC）的CHOICE-01试验结果的通俗语言总结。
Future Oncol. 2025 Feb;21(5):515-522. doi: 10.1080/14796694.2024.2426951. Epub 2024 Dec 4.
3
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer.TROPION-Breast05：一项随机III期研究，对比了在PD-L1高表达的局部复发不可切除或转移性三阴性乳腺癌患者中，使用或不使用度伐利尤单抗的德曲妥珠单抗（Dato-DXd）与化疗联合帕博利珠单抗的疗效。
Ther Adv Med Oncol. 2025 Apr 17;17:17588359251327992. doi: 10.1177/17588359251327992. eCollection 2025.
4
Cost-effectiveness analysis of toripalimab for metastatic or recurrent triple-negative breast cancer.托瑞帕利单抗用于转移性或复发性三阴性乳腺癌的成本效益分析。
Front Oncol. 2024 Jan 18;13:1268584. doi: 10.3389/fonc.2023.1268584. eCollection 2023.
5
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.特泊替尼联合白蛋白紫杉醇用于转移性或复发性三阴性乳腺癌：一项随机 3 期试验。
Nat Med. 2024 Jan;30(1):249-256. doi: 10.1038/s41591-023-02677-x. Epub 2024 Jan 8.
6
TORCHLIGHT trial, brightening the life of more patients with advanced triple-negative breast cancer.火炬之光试验，照亮更多晚期三阴性乳腺癌患者的生命。
Transl Breast Cancer Res. 2023 Sep 22;5:1. doi: 10.21037/tbcr-23-33. eCollection 2024.
7
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.TROPION-Breast02 研究：特泊替尼联合德曲妥珠单抗治疗局部复发不可切除或转移性三阴性乳腺癌。
Future Oncol. 2023 Nov;19(35):2349-2359. doi: 10.2217/fon-2023-0228. Epub 2023 Aug 1.
8
Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US.托瑞帕利单抗联合白蛋白结合型紫杉醇作为美国晚期三阴性乳腺癌一线治疗的成本效益分析
PLoS One. 2025 Apr 1;20(4):e0320727. doi: 10.1371/journal.pone.0320727. eCollection 2025.
9
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
10
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.特瑞普利单抗联合化疗用于复发或转移性鼻咽癌的随机对照临床研究（JUPITER-02 研究）
JAMA. 2023 Nov 28;330(20):1961-1970. doi: 10.1001/jama.2023.20181.

A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.

作者信息

Jiang Zefei, Ouyang Quchang, Sun Tao, Zhang Qingyuan, Teng Yuee, Cui Jiuwei, Wang Haibo, Yin Yongmei, Wang Xiaojia, Zhou Xin, Wang Yongsheng, Sun Gang, Wang Jingfen, Zhang Lili, Yang Jin, Qian Jun, Yan Min, Liu Xinlan, Yi Tienan, Cheng Ying, Li Man, Zang Aimin, Wang Shusen, Wang Chuan, Wu Xinhong, Cheng Jing, Li Hui, Lin Ying, Geng Cuizhi, Gu Kangsheng, Xie Chunwei, Xiong Huihua, Wu Xiaohong, Yang Junlan, Li Qingshan, Chen Yiding, Li Fanfan, Zhang Anqin, Zhang Yongqiang, Wu Yudong, Nie Jianyun, Liu Qiang, Wang Kun, Mo Xueli, Chen Lilin, Pan Yueyin, Fu Peifen, Zhang Helong, Pang Danmei, Sheng Yuan, Han Yunwei, Wang Hongxia, Cang Shundong, Luo Xianming, Yu Wenbo, Deng Rong, Yang Chaoqiang, Keegan Patricia

机构信息

Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.

Breast Internal Medicine Department, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

出版信息

Future Oncol. 2025 Feb;21(4):421-429. doi: 10.1080/14796694.2024.2430106. Epub 2024 Dec 4.

DOI:10.1080/14796694.2024.2430106
PMID:39628303
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11813204/
Abstract
摘要